Mexidol: A Stroke Drug, Not a Nootropic
Mexidol (2-ethyl-6-methyl-3-hydroxypyridine succinate) turns up on nootropic tier lists, and it does have real placebo-controlled trial data behind it — four randomized trials enrolling over a thousand patients between them. Every one of those patients had a diagnosis. Not one was a healthy adult looking to think more clearly.
How It Works
Mexidol is 2-ethyl-6-methyl-3-hydroxypyridine bound to succinate. A 2025 mechanism review attributes the antioxidant and membrane effects — including reduced glutamate excitotoxicity — to the 3-hydroxypyridine half, and the energy effects to the succinate half. (PMID: 40457664)
That same review describes succinate inducing the SUCNR1 receptor, stimulating mitochondriogenesis, restoring mitochondrial respiration and activating the Krebs cycle — the proposed basis of the antihypoxic effect. (PMID: 40457664)
The review also reports increased expression of HIF-1α and Nrf2 under hypoxic conditions, plus raised neurotrophic factors — NGF, IGF1, BDNF, VEGF — in areas of ischemic brain damage. Note the condition attached to every one of these: ischemia. (PMID: 40457664)
In rats given a single IV dose, succinate distributed evenly and was quickly eliminated. The rise was in the cytoplasmic fraction of liver, myocardium and cerebral cortex — largest in liver, less pronounced in cortex — with only a minor increase in the mitochondrial fraction, the compartment the energy story depends on. (PMID: 37338763)
A 2024 review in Drug Testing and Analysis compares Mexidol's metabolic and antihypoxic effects to meldonium and trimetazidine — both on the WADA Prohibited List under S4.4 Metabolic Modulators. It notes past confirmed use by Russian athletes, and that current use is unknown because Mexidol is not monitored or included in drug-testing protocols. If Mexidol does something in a healthy body, the evidence points here, not at cognition. (PMID: 38403950)
What the Data Shows
Key Takeaways
- Mexidol has a genuinely substantial randomized evidence base. Four double-blind placebo-controlled trials enrolled over a thousand patients between them, and that deserves saying plainly before any criticism lands.
- The strongest cognitive result is MEMO: 318 patients with chronic brain ischemia, aged 40-90, across 15 centers in Russia and Uzbekistan, randomized double-blind against placebo. MoCA change was the PRIMARY endpoint and Mexidol beat placebo decisively (p<0.000001), with the lower bound of the 95% CI for the between-group difference at 1.51. Secondary endpoints including the digit symbol substitution test also favored Mexidol. (PMID: 34932280)
- The MIR trial randomized 304 patients with ischemic stroke against placebo. (PMID: 40898634) It ran across 17 centers in Russia, Kazakhstan and Uzbekistan. (PMID: 41456191)
- In the earlier EPICA trial (150 randomized), mRS was lower than placebo at the end of treatment (p=0.04) and NIHSS was lower (p=0.035), with no statistically significant difference in side-effect frequency. (PMID: 28665371) A sub-analysis by age found efficacy did not differ across age groups. (PMID: 33016677)
- MEGA tested Mexidol in 333 children aged 6-12 with diagnosed ADHD across 14 Russian centers, double-blind against placebo. All three groups — including placebo — improved significantly on the combined SNAP-IV inattention and hyperactivity/impulsivity subscales over 42 days (p<0.05); the trial's case for the drug rests on the between-group differences, where both dosing arms separated from placebo (p=0.000308 and p=0.000024 in the per-protocol population). (PMID: 35485068)
- A 2024 meta-analysis of 10 prospective trials reported an effect size of 2.06 on final MoCA scores (95% CI for the between-group difference 0.98-3.14, p=0.0002), pooling 482 treated and 455 control patients with chronic brain ischemia and cognitive disorders — though here the comparator was basic therapy rather than placebo. (PMID: 38261288)
- Mexidol is a registered drug in Russia and Ukraine, sold under trade names including Mexidol, Mexicor and Armadin Long. (PMID: 38403950)
- Tolerability in the two stroke trials looks unremarkable: EPICA found no significant difference in adverse-event frequency (PMID: 28665371), and MIR reported adverse events in 23% of both the Mexidol and placebo groups (p=1.000). (PMID: 40898634) A separate analysis of randomized-trial data found no drug-interaction signal with common concomitant medications in ischemic stroke patients. (PMID: 41984565)
- Worth naming plainly: the mechanism reviews, the trials, the meta-analyses and the safety analyses overwhelmingly originate from a single national publishing ecosystem — most from one journal — and one of those reviews describes Mexidol as "the Russian original drug." That is not disqualifying, but independent replication elsewhere is what would settle it.
- Whether Mexidol does anything for a healthy adult's cognition. Every trial above enrolled a diagnosed population — stroke, chronic brain ischemia, ADHD. None enrolled healthy adults seeking enhancement. The only healthy-subject human data points elsewhere entirely: a 2009 study in volunteers aged 20-24 classed Mexidol an adaptogen and a "mental and physical actoprotector" under overcooling and hypobaric hypoxia (PMID: 20095399), and a 2024 review reports research in healthy subjects suggesting succinate-conjugated pyridine derivatives including Mexidol can enhance athletic performance (PMID: 38403950). Adapting to cold and running faster are not the claim being made on the tier lists.
- Whether correcting a deficit predicts enhancing a healthy baseline. This is the central inferential leap the tier lists make, and nothing in the literature licenses it. A drug that restores MoCA scores in a 70-year-old with cerebral hypoperfusion may do nothing at all in a healthy 25-year-old — the mechanism reviews attribute the effects to reversing ischemia and hypoxia, conditions a healthy brain is not in. (PMID: 40457664)
- Whether the results replicate outside the region that produced them. The 2023 stroke systematic review drew on 11 studies all published in Russian — only 2 randomized, the other 9 non-randomized and unblinded — and its own authors reported significant statistical heterogeneity and said the evidence requires further examination as new data emerge. (PMID: 38148698)
- Whether a dose meaningfully reaches brain mitochondria in a person who is not ischemic. Even an intravenous dose in rats produced only a minor rise in the mitochondrial fraction of brain cortex, with succinate rapidly eliminated. (PMID: 37338763)
- Long-term safety beyond the trial treatment windows, which were short: 42 days in MEGA (PMID: 35485068), and about 70 days in MIR — 10 days of intravenous Mexidol followed by 60 days of oral Mexidol FORTE 250, with the primary endpoint assessed at the end of therapy. (PMID: 40898634)
- How Mexidol compares head-to-head against modafinil, cerebrolysin, or semax — no trial has run that comparison, despite tier lists ranking them together.
- Its legal status is not ambiguous, and that matters: an independent 2023 review classifies emoxypine (Mexidol) as an unapproved pharmaceutical appearing as an unauthorized ingredient in supplements sold as nootropics. It is not FDA- or EMA-approved. (PMID: 37357012)
Frequently Asked Questions
Is Mexidol actually an S-tier nootropic?
Not on the evidence, though the answer is more interesting than a flat no. Mexidol has multiple double-blind placebo-controlled trials behind it, and one of them, MEMO, used a cognitive score as its primary endpoint and beat placebo decisively. But every trial enrolled a diagnosed population — stroke, chronic brain ischemia, ADHD. Not one enrolled healthy adults. Ranking it S-tier for cognitive enhancement takes a result obtained in impaired brains and assumes it transfers to healthy ones, which no study has tested.
What is Mexidol and where is it approved?
Mexidol is 2-ethyl-6-methyl-3-hydroxypyridine succinate (emoxypine succinate), a synthetic derivative of vitamin B6 developed in Russia. It is a registered drug in Russia and Ukraine under trade names including Mexidol, Mexicor and Armadin Long, prescribed for stroke and cerebrovascular conditions. (PMID: 38403950) It is not approved by the FDA or the EMA. A 2023 review in Drug Testing and Analysis lists emoxypine among unapproved pharmaceuticals turning up as unauthorized ingredients in supplements marketed as nootropics. (PMID: 37357012)
Does Mexidol improve cognition?
In people who already have cognitive impairment, yes — with real trial support. The MEMO trial randomized 318 patients with chronic brain ischemia against placebo using MoCA change as its primary endpoint, and Mexidol won at p<0.000001, with the lower bound of the 95% confidence interval for the between-group difference at 1.51 points. (PMID: 34932280) A separate meta-analysis of 10 prospective trials found a 2.06-point MoCA advantage over basic therapy (95% CI 0.98-3.14, p=0.0002). (PMID: 38261288) Both were conducted in impaired populations. Whether any of this transfers to a healthy brain is untested.
Is there any research on Mexidol in healthy people?
Some, but none of it about cognitive enhancement. A 2009 study in healthy volunteers aged 20-24 tested antihypoxic drugs in a climate thermobarocomplex and concluded Mexidol acts as an adaptogen and a mental and physical actoprotector under overcooling and hypobaric hypoxia. (PMID: 20095399) A 2024 review reports that available research on healthy subjects suggests succinate-conjugated pyridine derivatives including Mexidol can enhance athletic performance. (PMID: 38403950) Both concern performance under physical stress, not baseline cognition at a desk.
Is Mexidol a doping agent?
As of the 2024 review, it is not on the WADA Prohibited List — but the question is live. That review compared Mexidol's metabolic and antihypoxic effects to meldonium and trimetazidine, both of which ARE listed under category S4.4 Metabolic Modulators. It states past use by Russian athletes has been confirmed, and that current use is unknown because Mexidol is not monitored or included in drug-testing protocols. If you compete in a tested sport, that is a live risk worth understanding rather than a settled all-clear. (PMID: 38403950)
Does Mexidol work for ADHD?
One large trial says it helps. MEGA randomized 333 children aged 6-12 with ADHD diagnosed by ICD-10 and DSM-5 criteria across 14 Russian centers, double-blind against placebo over 42 days. Both Mexidol dosing arms significantly outperformed placebo on the combined SNAP-IV inattention and hyperactivity/impulsivity subscales (p=0.000308 and p=0.000024 in the per-protocol population). (PMID: 35485068) It is a single trial in children, conducted in one country, and has not been replicated independently.
How strong is the stroke evidence?
Moderate and geographically concentrated. In the EPICA trial (n=150), the modified Rankin Scale was lower than placebo at the end of treatment (p=0.04). (PMID: 28665371) The larger MIR trial (n=304) also tested Mexidol against placebo in ischemic stroke. (PMID: 40898634) A 2023 systematic review pooling 11 studies found benefit but noted only 2 were randomized, all 11 were published in Russian, and heterogeneity was significant. Independent replication outside the region is the missing piece. (PMID: 38148698)
Is there any independent non-Russian research on Mexidol?
Very little, and none of it is efficacy research. The independent non-Russian literature that does exist is regulatory and analytical rather than clinical: a 2023 review in Drug Testing and Analysis lists emoxypine (Mexidol) among unapproved pharmaceuticals appearing as unauthorized ingredients in supplements marketed as nootropics (PMID: 37357012), and a 2024 review in the same journal examines Mexidol as a metabolic modulator and possible performance-enhancing drug (PMID: 38403950). Neither one tests whether it works. The randomized trials — EPICA, MIR, MEMO, MEGA — were conducted and published within a single regional research ecosystem — Russia and neighbouring post-Soviet states — which is exactly why independent replication keeps coming up as the missing piece.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
Mexidol is not approved by the FDA or the EMA. It is a prescription drug in Russia and several neighboring countries, and it is not an authorized dietary supplement ingredient in the United States or the European Union.
Nothing here is a recommendation to obtain or use Mexidol. This page exists to describe what the published trials measured, and in whom.